<DOC>
	<DOCNO>NCT02323191</DOCNO>
	<brief_summary>This Phase 1 , open-label , multicenter , global study evaluate safety , pharmacokinetics , activity RO5509554 MPDL3280A administer combination patient select locally advanced metastatic solid tumor amenable standard treatment . Patients receive MPDL3280A RO5509554 continue receive study drug long experience clinical benefit opinion investigator unacceptable toxicity symptomatic deterioration attribute disease progression determine investigator integrate assessment radiographic data , biopsy result ( available ) , clinical status , withdrawal consent .</brief_summary>
	<brief_title>A Study RO5509554 MPDL3280A Administered Combination Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; /= 18 year Eastern Cooperative Oncology Group performance status 0 1 Patients must histologically confirm diagnosis locally advance and/or metastatic triple negative breast cancer , ovarian cancer , bladder cancer , gastric cancer , soft tissue sarcoma , exception define protocol Radiologically measurable clinically evaluable disease ( per Response Evaluation Criteria Solid Tumors [ RECIST ] version 1.1 ) Life expectancy &gt; /= 16 week Adequate bone marrow , liver , cardiac , renal function Negative serum pregnancy test within 7 day prior study treatment premenopausal woman woman &lt; /= 2 year postmenopause . Menopause define amenorrhea &gt; 2 year . For woman postmenopausal surgically sterile men partner childbearing potential , agreement use highly effective contraceptive method ( ) study period least 6 month last dose study drug Allergy hypersensitivity component either study drug formulation Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance image evaluation screening ( within 28 day Cycle 1 Day 1 ) prior radiographic assessment . Patients radiographically stable , asymptomatic previously irradiate lesion eligible provide patient &gt; /= 4 week beyond completion cranial irradiation &gt; /= 3 week corticosteroid therapy . Patients metastases brain stem , midbrain , pons , medulla , within 10 mm optic apparatus ( optic nerve chiasm ) completely exclude . Leptomeningeal disease History active autoimmune disease Evidence significant , uncontrolled concomitant disease , could affect compliance protocol interpretation result , include significant cardiovascular disease ( New York Heart Association Class III IV cardiac disease , myocardial infarction within last 6 month , unstable arrhythmia , unstable angina ) pulmonary disease ( include obstructive pulmonary disease history symptomatic bronchospasm ) Any approve anticancer therapy , include chemotherapy hormonal therapy , within 3 week prior initiation study treatment , exception provide protocol Prior corticosteroid anticancer therapy within minimum 14 day first receipt study drug Prior toxicity chemotherapy radiotherapy regress Grade &lt; /= 1 severity ( CTCAE v4.03 , late version ) History HIV Patients active hepatitis B , active hepatitis C , active tuberculosis Patient pulmonary embolism thromboembolic event within 6 month prior study entry Patient history hematological malignancy within last 5 year prior study entry Treatment systemic immunosuppressive medication Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>